(Q34167016)

31 July 2017

1 reference

title

Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth (English)

1 reference

31 July 2017

0 references

Pseudomonas aeruginosa

0 references

C Moser

3

0 references

Oana Ciofu

object named as

O Ciofu

5

0 references

author name string

N Høiby

1

1 reference

31 July 2017

H Krogh Johansen

2

1 reference

31 July 2017

Z Song

4

1 reference

31 July 2017

A Kharazmi

6

1 reference

31 July 2017

publication date

1 January 2001

1 reference

31 July 2017

published in

Microbes and Infection

1 reference

31 July 2017

volume

3

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

23-35

1 reference

Biofilms, the customized microniche

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

In situ gene expression in mixed-culture biofilms: evidence of metabolic interactions between community members

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Transport of 1-microm latex particles in pseudomonas aeruginosa biofilms

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Optical sectioning of microbial biofilms

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

The involvement of cell-to-cell signals in the development of a bacterial biofilm

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Bacteriophages in sputum of cystic fibrosis patients as a possible cause of in vivo changes in serotypes of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

In vitro and in vivo changes of serotype in Pseudomonas aeruginosa isolates by anti-pseudomonal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Inhibition of tobramycin diffusion by binding to alginate

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Testing the susceptibility of bacteria in biofilms to antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Testing antimicrobial susceptibilities of adherent bacteria by a method that incorporates guidelines of the National Committee for Clinical Laboratory Standards.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

The efficacy of antibiotics enhanced by electrical currents against Pseudomonas aeruginosa biofilms

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

The effect of ultrasonic frequency upon enhanced killing of P. aeruginosa biofilms.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Photomechanical drug delivery into bacterial biofilms

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Pathogenesis of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients: evidence for intestinal colonization and spreading into toilets

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Pseudomonas aeruginosa colonization of the gastrointestinal tract in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Pulmonary dehydration and infection in cystic fibrosis: evidence that ethanol activates alginate gene expression and induction of mucoidy in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Host inflammatory responses to first isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Serum antibodies to Pseudomonas aeruginosa outer-membrane proteins and iron-regulated membrane proteins at different stages of chronic cystic fibrosis lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronicPseudomonas aeruginosalung infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Cytokines in sputum and serum from patients with cystic fibrosis and chronicpseudomonas aeruginosa infection as markers of destructive inflammation in the lungs

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Current understanding of the inflammatory process in cystic fibrosis: onset and etiology

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

The role of immune complexes in the pathogenesis of bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Excretion of urinary collagen metabolites correlates to severity of pulmonary disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 typeNote

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Bacterial quorum sensing in pathogenic relationships

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Pseudomonas aeruginosa biofilms are more susceptible to ciprofloxacin than to tobramycin

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Effect of subinhibitory concentrations of Ciprofloxacin and gentamicin on the adherence of Pseudomonas aeruginosa to Vero cells and voided uroepithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Alterations in Pseudomonas aeruginosa exoproducts by sub-MICs of some antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Subinhibitory antibiotics reduce Pseudomonas aeruginosa tissue injury in the rat lung model

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Subinhibitory concentrations of tetracycline inhibit surface expression of the Pseudomonas aeruginosa ferripyochelin binding protein in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Therapeutic possibilities for diffuse panbronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Inflammatory markers in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Long-term azithromycin may improve lung function in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

The influence of allotypes on the IgG subclass response to chromosomal beta-lactamase of Pseudomonas aeruginosa in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Effect of high-dose ibuprofen in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Controlled Trial of Inhaled Budesonide in Patients with Cystic Fibrosis and Chronic BronchopulmonaryPseudomonas aeruginosaInfection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Aerosol α1 -antitrypsin treatment for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Ginseng treatment reduces bacterial load and lung pathology in chronic Pseudomonas aeruginosa pneumonia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Mechanisms involved in the evasion of the host defence by Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901349-6

7 January 2021

10.1016/S1286-4579(00)01349-6

Identifiers

DOI

1 reference

31 July 2017

1 reference